baseline cholesterol levels and relevant co-morbidity. RESULTS: A total of 2341 patients were identified, of these 644 were initiated on rosuvastatin (93% on 10 mg), 606 on atorvastatin (53% on 10 mg, 39% on 20 mg), 613 on simvastatin (70% on 20 mg), 440 on pravastatin (79% on 40 mg) and 38 on fluvastatin (79% on 80 mg). Secondary prevention accounted for approximately 30% of patients. Average percent LDL-C reductions were 48.0 (CI95%: 46.6–49.5), 41.7 (CI95%: 39.9–43.4), 38.7 (CI95%: 37.3–40.0), 32.0 (CI95%: 30.1–33.9), and 29.7 (CI95%: 23.9–35.5) for rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin respectively. The proportion of patients attaining cholesterol goals was 75% for rosuvastatin, 68% for atorvastatin, 56% for simvastatin, 42% for pravastatin, and 34% for fluvastatin. After adjustment for risk factors the use of rosuvastatin was significantly associated with both greater LDL-C reduction (mean differences 5.4% to 18.3%, all p < 0.001), and with increased goal attainment (odds ratios 0.60 to 0.11, all p < 0.001) compared to users of other statins. CONCLUSION: We found evidence that in a real life setting, both percentage LDL-C reduction and the proportion of patients attaining 2003 European cholesterol goals is significantly greater among users of rosuvastatin compared to other statins. Results are consistent with those reported in clinical trials.

RESOURCE UTILIZATION AND COSTS FOLLOWING HOSPITAL INPATIENT ADMISSION FOR CONGESTIVE HEART FAILURE
Gemmen EK1, Bharml M1, Zyczynski T2
1Quintiles Strategic Research Services, Falls Church, VA, USA, 2GE Healthcare, Princeton, NJ, USA
OBJECTIVE: To examine Medicare resource utilization and costs among patients with congestive heart failure (CHF) over the course of one year after an initial CHF hospital discharge. METHODS: Statistical analyses were conducted on Medicare Standard Analytic Files. A cohort of patients with an initial inpatient hospitalization for CHF between January 1, 1999 and December 31, 2000 were identified and followed for a period of one year. Outcomes assessed included the number of readmissions (CHF-related and all-cause) and emergency department (ED) visits; the mean time to each readmission/visit; mortality following discharge; number and timing of physician office visits; and total charges. Multivariate regression analyses were conducted to assess the likelihood of hospital readmission, likelihood of death, and total charges adjusting for patient characteristics and compliance with routine care. RESULTS: A cohort of 690,800 patients (weighted) was identified. Within one year of their initial hospitalization, approximately 20 percent of patients (136,460; 19.75%) were readmitted for CHF and over one-half (350,660; 50.76%) were readmitted for all causes. The time-to-event analysis revealed that increasing the time to first readmission decreases the overall number of readmissions and associated costs. Over 50% of patients visited the ED within 3 months of hospital discharge. The one-year mortality rate was 31.4%. The patient population that was readmitted within 30 days of initial hospital discharge accumulated the highest total charges over the course of the year (mean = $66,639). In the multivariate model, the main cost drivers were the number of hospital readmissions and death anytime within the year (potentially due to high end-of-life costs). CONCLUSIONS: The large proportion of hospital readmissions and ED visits occurring shortly after discharge suggests that many patients are not sufficiently managed once outside the hospital. Increased compliance with physician visits could help decrease the overall number of both CHF-related and all-cause readmissions.

REAL WORLD MORTALITY OF THE HYPERTENSIVE PATIENT AS DEFINED IN THE ASCOT-LLA
F Bobadilla J1, Sicras A2, Moreno R1, Garcia Puig J1, Garcia M3, Navarro R2, Soto J1
1Pérez Spain, Alcobendas, Madrid, Spain, 2Badalona Servicios Asistenciales, Badalona, Barcelona, Spain, 3San Carlos Clinical Hospital, Madrid, Madrid, Spain, 4La Paz University Hospital, Madrid, Madrid, Spain, 5Eurocin Institute, Alcobendas, Madrid, Spain
All cause mortality in the placebo group of ASCOT-LLA (Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering arm) was 1.28%. ASCOT-LLA included hypertensive patients (HP) in primary prevention, with TC ≥ 6.5 mmol/L, not treated with statins and with at least 3 cardiovascular risk factors (CVRF). A lower CV morbimortality with atorvastatin ten mg vs placebo was demonstrated. OBJECTIVES: Evaluate the real world mortality of HP as defined in ASCOT-LLA in a Mediterranean population of HP not treated with statins. METHODS: Patients from seven primary care centres with a diagnosis of HT (CIAP K86-K87) were included in a multicentric registry of one year follow-up (2004–2005) (n = 6309 patients). Main analysed variables were: basal age-sex, diabetes mellitus, stroke, smoking, TC/HDL-ratio and all cause mortality (2004). RESULTS: Of the 6309 patients, 2528 (40%) had a history of CHD and/or heart failure (HF) and/or TC > 6.5 mmol/L and/or statin treatment and were excluded from the analysis. In the remaining 3781, CVFR ≥ 3 was confirmed in 831. The annual mortality of these patients was 2.89%, greater than ASCOT-LLA placebo group. In the group of 3781 patients with no history of cardiac disease nor TC > 6.5 mmol/L and without statin treatment, those with CVRF ≥ 3 had a higher mortality (2.89%) vs CVRF < 3 (1.86%) (Fisher: p = 0.0497; χ²:p = 0.0795). A significant relationship was demonstrated among CVRF number and mortality: 0 CVRF-0% mortality; 1 CVRF:1.4% mortality; 2 CVRF:2.7% mortality; 3 CVRF:2.0% mortality; 4 CVRF:4.8% mortality; ≥5 CVRF:5.9% mortality (Mantel-Haenzel test: p = 0.003). CONCLUSIONS: Our data suggest that real world mortality of ASCOT-like hypertensives in a Mediterranean population is greater than the mortality found in the ASCOT (2.89% vs. 1.29%). A significant relationship was demonstrated among CVRF and mortality. Our data also suggest that the presence of CVRF ≥ 3 indicates a high mortality risk.

ECONOMIC STUDIES II
RIMONABANT FOR THE TREATMENT OF OVERWEIGHT AND OBSE INDIVIDUALS AT INCREASED CARDIOMETABOLIC RISK: AN ECONOMIC EVALUATION USING DISCRETE EVENT SIMULATION
Getssios D1, Moller J2, Ishak KJ3, McEwan P1, Danel A1, Caro JJ1
1Caro Research Institute, Halifax, NS, Canada, 2Caro Research Institute, Eslov, Sweden, 3Caro Research Institute, Montreal, QC, Canada, 4Cardiff Research Consortium, Cardiff, UK, 5Sanofi-Aventis, Paris Cedex 12, Paris, France, 6Caro Research Institute, Concord, MA, USA
OBJECTIVE: Rimonabant, the first selective CB-1 receptor blocker, has proven effective in improving cardiometabolic risk factors and reducing weight in overweight and obese individuals. This study evaluated its cost-effectiveness in patients with a BMI > 27 kg/m2 in the UK. METHODS: A discrete event simulation was created to take into account multiple time-dependent risk factors—it predicts changes in anthropomorphic and physiologic parameters based on analysis of pooled RIO trials data, while simultaneously predicting onset of diabetes, cardiocircu-
lar events and diabetic complications. After 100,000 individuals are assigned baseline characteristics by sampling UK data, their baseline risks are predicted and they enter a main module where these are applied. Periodic updating takes place at doctors’ visits and other events, such as premature treatment discontinuation and complications. Resource use, costs and utilities were obtained from UK databases. All outcomes are discounted at 3.5%/year. RESULTS: After one year treatment, patients on rimonabant plus diet and exercise lose more than three times the weight and show greater improvements in other cardiometabolic risk factors than patients on diet and exercise alone. With diet and exercise, 633 cardiovascular and 411 microvascular events are predicted to occur per 1000 patients, over 60 years. Lifetime costs average ≤692/patient. One year of rimonabant reduces cardiovascular and microvascular events by 18 and 10, respectively, with a corresponding reduction in complication costs. Discounted life expectancy increases by 40.2 years, and QALYs by 113.8. Extending treatment to 5 years increases life years and QALYs gained by a further 38 and 48%, respectively. Extensive sensitivity analyses, including varying the cost of treatment with rimonabant, indicate that rimonabant is cost-effective over a wide range of inputs. CONCLUSIONS: Rimonabant for the treatment of overweight or obese patients with or without comorbidities in the UK should be associated with acceptable cost-effectiveness ratios under a wide range of assumptions.

ENTRY AND PRICE RESPONSE IN MARKETS WITHOUT PATENT PROTECTION: THE CASE OF PHARMACEUTICALS IN ARGENTINA
Maceira DA
Center for the Study of the State and Society, Ciudad Autónoma de Buenos Aires, Argentina
OBJECTIVES: The goal of this paper is to test the leader-follower model in the Argentinean pharmaceutical markets where patent protection does not apply allowing immediate entry. METHODS: It was used a leader-follower model where followers take leader prices to decide their own ones and the leader strategically incorporates followers’ behavior in its decision. Two different groups of followers are studied separating the main three from the rest of the market competitors. The data used in this study is based in information published by Pharmaceutical Markets Argentina (PMA) complemented with indicators of needs and chronicity, obtained through interviews with physicians and pharmacologists, as well as the list of chemical entities used in the production of each product, and the nationality of manufacturers. RESULTS: From the group of 88 therapeutic classes selected, 56 classes kept the same leader during the period 1988–1995, although just in nine of those cases the first entrant remains as market leader. The cases where market leader remains the same during the sample period but they were not necessarily the first entrants are defined as loose leadership markets, while cases of strict leadership are those where first entrant remains as market leader during the sample period. CONCLUSIONS: The leader-follower hypothesis is checked and supported by the data, mirroring the results obtained under a patent regime. In addition, the lack of patents also raises the question of difference in behavior among followers. Therefore, two differentiated groups of followers are studied separating the main three from the rest of the market competitors.